# Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

> **NCT07670026** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 31 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab
- **RADIATION:** Postoperative Radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07670026
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670026, "Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07670026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*